Antibiotic Resistance Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Antibiotic Resistance Market Analysis

The antibiotic resistance market was valued at USD 8.5 billion in the base year and is expected to be valued at USD 10.5 billion, registering a CAGR of 5.4 over the forecast period.

The COVID-19 pandemic had an impact on the antibiotic resistance market. As per an article published in March 2022 by the Pan American Health Organization, the COVID-19 pandemic fueled the ongoing antimicrobial resistance (AMR) global crisis due to the increase in the use of antibiotics to treat COVID-19 patients. Moreover, disruptions to infection prevention and control practices in overwhelmed health systems and diversion of human and financial resources away from monitoring and responding to AMR threats. Therefore, the market witnessed high growth during the pandemic. However, as per the study published in March 2023 by the National Library of Medicine, emerging data from the United States Centers for Disease Control and Prevention suggests the pandemic has resulted in rising rates of AMR, including carbapenem-resistant Acinetobacter and extended-spectrum beta-lactamase-producing Enterobacterales. Therefore, it is expected to observe high growth after the pandemic.

The increasing burden of antibiotic-resistant infections across developed & developing regions and a shift in prescription patterns to newly launched therapies are the key drivers of the market. Moreover, the increasing involvement of Government and non-government bodies in developing novel therapies is anticipated to drive market growth. The high burden of antibiotic-resistant infections is a major concern globally. For instance, as per the CDC's data published in October 2022, in the United States, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result of antibiotic resistance.

Moreover, in February 2023, the Australian Government raised USD 6 million in funds for research into antimicrobial resistance and reducing the incidence of hospital infections. This grant opportunity was announced as part of the Medical Research Future Fund (MRFF) under the Global Health Initiative. Thus, such initiatives taken by the Government are expected to boost the market's growth over the forecast period.

Some major companies operating in the AMR are adopting several strategies, such as collaboration and acquisition, along with various launches to strengthen their positions in the market. For instance, in January 2023, Alkem Laboratories launched an antibiotic, Zidavi, for multiple drug-resistant (MDR) infections. Moreover, in January 2023, Molbio Diagnostics launched Truenat MTB-INH for testing the presence of isoniazid resistance in Mycobacterium tuberculosis in infection (MDR-TB). The test is validated by ICMR and approved by CDSCO, which can provide sample-to-test results in an hour.

However, strict safety guidelines and the high cost of AMR therapeutics are expected to hinder the market's growth.

Antibiotic Resistance Market Trends

Complicated UTIs Segment Expected to Hold a Major Share in the Market

Antibiotic Resistance Industry Segmentation

As per the scope of the report, antibiotic resistance occurs when bacteria change in response to the use of these medicines. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. The antibiotic Resistance Market is segmented By Disease (Clostridioides Difficile Infection (CDI), Complicated Intra-Abdominal Infection (cIAI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital-Acquired and Ventilator-Associated Bacterial Pneumonias (HABP), Complicated Urinary Tract Infection (cUTI), Community-Acquired Pneumonia (CABP), and Bloodstream Infection (BSI)), By Pathogen (Acinetobacter baumannii, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, E. Coli, and Other Pathogens), Drug Class (Tetracyclines, Oxazolidinones, Cephalosporins, Lipoglycopeptides, Combination therapies, and Other Drug Classes), Mechanism of Action (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA synthesis inhibitors, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD) for the above segments.